Trial Profile
A Phase I, Open-Label, Non-Randomised, Multicentre Study to Assess the Effect of AZD9291 on the Pharmacokinetics of Rosuvastatin (a Sensitive BCRP Substrate) in Patients With EGFRm Positive NSCLC Whose Disease Has Progressed on an EGFR TKI
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary) ; Rosuvastatin (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 01 Sep 2018 Results published in the British Journal of Clinical Pharmacology
- 02 Jul 2018 Status changed from active, no longer recruiting to completed.
- 17 Jan 2018 Planned End Date changed from 4 Jan 2018 to 31 Dec 2018.